(Q37867169)

24 August 2017

0 references

1 reference

title

Meta-analysis of dermatological toxicities associated with sorafenib (English)

1 reference

24 August 2017

0 references

L Zhang

1

1 reference

24 August 2017

Q Zhou

2

1 reference

24 August 2017

L Ma

3

1 reference

24 August 2017

Z Wu

4

1 reference

24 August 2017

Y Wang

5

1 reference

24 August 2017

publication date

20 April 2011

1 reference

Clinical and Experimental Dermatology

24 August 2017

published in

1 reference

24 August 2017

volume

36

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

344-350

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Phase II trial of sorafenib in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

Management of vascular endothelial growth factor and multikinase inhibitor side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2011.04060.X

10.1111/J.1365-2230.2011.04060.X

21 January 2018

Identifiers

DOI

1 reference

release_q6ugqvqgwzcenaiytx2cbsochm

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q6ugqvqgwzcenaiytx2cbsochm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference